Phentermine/Topiramate-First

Phase 1Small molecule

SStanford University

Phentermine/Topiramate-First is one of 8 small molecule programs targeting Binge Eating. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Binge EatingActive, not recruiting

Binge EatingPhase 1

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Binge Eating

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

2 2

Revia

Meridia

1 4

Topamax

WWim Janssens

Approved

—5

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 2

1 6

Lisdexamfetamine Dimesylate

Takeda

Preclinical

—7

GLP-1

RRigshospitalet, Denmark

Preclinical

1 8

Phentermine/Topiramate-First

SStanford University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Binge Eating1 trial

FDA Approved Medication to Reduce Binge Eating and/or Purging

Completed·SStanford University·Phase 1·NCT02553824·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Phentermine/Topiramate-First. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phentermine/Topiramate-First compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phentermine/Topiramate-First. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SStanford University

Phentermine/Topiramate-First

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Binge Eating1 trial

References

Drug Info

Quick Facts

Related News